Smith & Nephew’s US Advanced Wound Management division recently announced that the FDA has given clearance of its newest absorbent antimicrobial barrier dressing, ACTICOAT™ Moisture Control.
The clearance and introduction of ACTICOAT™ Moisture Control complements the company’s existing ACTICOAT™ range. These are the only wound care products to feature the patented Silcryst nanocrystalline silver technology that provides antimicrobial barrier protection.
ACTICOAT™ Moisture Control was developed over the last two years, through collaboration between Smith & Nephew and NUCRYST Pharmaceuticals. Smith & Nephew launched the product at the SAWC Convention on April 22nd in San Diego, as an extension to the existing ACTICOAT™ family.
The current ACTICOAT™ range, which encompass a three day, seven day and absorbent product have been shown to be bactericidal against a broad range of pathogens, including MRSA and VRE, and have led the way in both burn and chronic wound care. ACTICOAT™ Moisture Control, with an extended wear time up to 7 days, reduces the number of dressing changes and the resources needed to change multiple dressings, adding to the comfort and quality of life of the patient.
Antimicrobial barrier dressings are increasingly used in the advanced wound care market as a barrier to bacterial penetration, a major cause of delays and complications to wound healing. As an effective barrier to pathogenic bacteria, ACTICOAT™ Moisture Control may help avoid serious complications associated with nosocomial outbreaks, wound infection may be avoided and duration of hospitalization and healthcare related costs reduced proportionately.
